Bispecific CD19-CD20 CAR for Persistent B Cell Cancer Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR therapies for B cell malignancies face challenges in achieving clinical effectiveness due to variable T cell quality, anergy, suppression, or exhaustion, limiting the persistence and proliferation of CAR-transformed T cells, and the need for improved therapies that can target CD20 and CD22.
Innovation Solution
Development of novel antigen binding domains and Chimeric Antigen Receptors (CARs) that specifically bind to CD20 and CD22, combined with B-cell inhibitors like CD19, to enhance T cell persistence and proliferation, utilizing nucleic acids encoding these domains for therapeutic applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional CAR therapies targeting single antigens (e.g., CD19) are used, then initial anti-tumor activity is achieved, but T cell persistence and proliferation are limited due to anergy, suppression, or exhaustion
Solution Approach 1:
The patent combines multiple antigen targets (CD19 and CD20) into a single bispecific CAR construct, allowing T cells to simultaneously recognize and respond to both antigens. This merging of targeting capabilities prevents T cell exhaustion by providing diverse antigen recognition, thereby improving persistence and prolonged proliferation without requiring separate CAR populations
Solution Approach 2:
The bispecific CAR design赋予T cells multi-functionality by enabling them to target multiple B cell malignancy markers (CD19 and CD20) through a single receptor construct. This universal targeting approach enhances therapeutic reliability by ensuring T cells can maintain anti-tumor activity against heterogeneous tumor populations, preventing anergy and suppression
2Reliability
If T cells are engineered with high specificity to tumor antigens, then therapeutic efficacy is improved, but variable T cell quality and immune suppression limit clinical effectiveness
Solution Approach 1:
By merging CD19 and CD20 binding specificities into a single bispecific CAR, the patent creates a standardized construct that delivers consistent dual-targeting capability across all engineered T cells. This approach reduces variability in T cell quality by ensuring uniform antigen recognition profiles, thereby improving reliability of therapeutic efficacy while maintaining adaptability to different tumor contexts
Solution Approach 2:
The bisspecific CAR functions as a composite molecular construct combining antigen-binding domains for both CD19 and CD20, along with signaling and costimulatory domains. This composite design ensures that all engineered T cells possess identical multi-functional capabilities, reducing quality variability while enhancing therapeutic efficacy through coordinated dual-target engagement
3Ease of manufacture
If single-antigen CAR therapies are used, then treatment simplicity is maintained, but the ability to survey for leukemic relapse and maintain long-term persistence is compromised
Solution Approach 1:
The patent merges dual antigen targeting (CD19 and CD20) into a single CAR construct that can be manufactured and administered as one unified therapy. This approach maintains relative simplicity in manufacturing and clinical administration while enabling long-term persistence through enhanced T cell survival signals and reduced exhaustion, eliminating the need for complex multi-therapy regimens
Data Source
AI summary
The invention provides compositions and methods for treating diseases associated with expression of CD20 or CD22. The invention also relates to chimeric antigen receptor (CAR) specific to CD20 or CD22, vectors encoding the same, and recombinant T or natural killer (NK) cells comprising the CD20 CAR or CD22 CAR. The invention also includes methods of administering a genetically modified T cell or NK cell expressing a CAR that comprises a CD20 or CD22 binding domain.